Arecor Therapeutics PLC (AREC)
London Exchange · UK · prices in GBX · close of 20 Oct 2026
Key indicators
| Last close | GBX 82.50 |
|---|---|
| 52-week range | 55.27 – 95.00 |
| Return, 1 month / 3 months | −5.7% / +29.9% |
| Return, 1 year / 3 years | +21.3% / −56.6% |
| Trend | Uptrend |
| RSI (14) | 64 |
| Volatility (1 year) | 34.4% |
| Worst drawdown (1 year) | -37.8% |
| Average daily value traded | 2.44M GBX |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Arecor Therapeutics is a biopharmaceutical company based in the United Kingdom that works on reformulating protein and peptide medicines. Using its own formulation technology, it develops improved versions of existing injectable drugs, including insulin products, with the aim of making them more stable or convenient for patients. The company also partners with other pharmaceutical firms that license its technology, and it advances its own pipeline of treatments for diabetes and other conditions.
Arecor Therapeutics PLC trades under the code AREC on the London Exchange in UK, with its price quoted in pence sterling (GBX). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Arecor Therapeutics PLC (AREC) trades on the London Exchange in UK. It last closed at GBX 82.50 on 20 October 2026.
Its price-based Market X-Ray is 66 out of 100 (a fair price profile), ranking 834 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 21.3% and over the last three months it rose 29.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 73 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 17.1% | ||
| From 52-week high | -10.8% | ||
| Momentum | 84 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 29.9% | ||
| 6-month return | 25.0% | ||
| 12-month return, skipping the last month | 28.7% | ||
| Stability (higher is calmer) | 43 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 34.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -37.8% | ||
| Liquidity | 62 · Fair | Moderate trading activity. | |
| Average daily value traded | 2.44M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +10.0% |
|---|---|
| 1 month | −5.7% |
| 3 months | +29.9% |
| 6 months | +25.0% |
| 1 year | +21.3% |
| 3 years | −56.6% |
| 5 years | −79.6% |
Signals
| 50-day / 200-day average | 75.15 / 70.48 |
|---|---|
| Golden / death cross (60 days) | Golden, 14 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 4.57 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.